You just read:

Janssen Announces Two-drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in Maintaining Viral Suppression in Phase III Clinical Studies

News provided by

Janssen Sciences Ireland UC

Feb 13, 2017, 18:56 ET